# Intraganglionic injections into mouse DRG? **URL:** \ **Category:** Protocols\ **Created:** [July 11, 2016, 10:23pm UTC](https://forum.painresearcher.net/t/intraganglionic-injections-into-mouse-drg/56 "2016-07-11T22:23:33Z")\ **Posts on this page:** 20\ **Page:** 1
**Author:** ![achamess](https://yyz2.discourse-cdn.com/flex030/user_avatar/forum.painresearcher.net/achamess/32/534_2.png) [@achamess](https://forum.painresearcher.net/u/achamess)\ **Post date:** [July 11, 2016, 10:23pm UTC](https://forum.painresearcher.net/t/intraganglionic-injections-into-mouse-drg/56/1 "2016-07-11T22:23:33Z")
I’m needing to inject viral vectors directly into mouse DRG so that I can localize the expression just to the DRG. I can get very good expression when I inject intrathecally, but that enables the spread of the virus to parts of the CNS where I don’t want it to go. So I need to do an intra-DRG injection. I know it can be done. A recent paper by [Vicuna et al](http://www.nature.com/nm/journal/v21/n5/full/nm.3852.html). in Nat. Med used intraganglionic injection to control transgene expression. And I know it can be done in the rat, but for mouse, I don’t have a detailed protocol. I know that I will need to expose a DRG (lumbar, L4 probably), which will require some kind of laminectomy or small bone removal. It’d be great if anyone has some in-house protocols with images/video to help me perform this procedure. Also, if you’ve injected virus, some info on the volume and titer would be great. @tberta do you have any thoughts on this? ---
**Author:** ![tberta](https://yyz2.discourse-cdn.com/flex030/user_avatar/forum.painresearcher.net/tberta/32/145_2.png) [@tberta](https://forum.painresearcher.net/u/tberta)\ **Post date:** [July 12, 2016, 1:08am UTC](https://forum.painresearcher.net/t/intraganglionic-injections-into-mouse-drg/56/2 "2016-07-12T01:08:49Z")
Raquel, my postdoc, will start this kind of experiment in the next weeks and I am sure that she will share any information that may help you. Our starting point is to replicate (more or less) what it was done by the same group in their previous [publication](http://journals.plos.org/plosbiology/article?id=10.1371/journal.pbio.1001283): “Virions were diluted 1∶2 with 20% mannitol and injected unilaterally into L3 and L4 DRGs (1 µl per DRG, or approx. 107 transfection units per DRG)”. There is an impressive image of the GFP expression 2 weeks after injection. To get to the DRGs, we will use the same approach that it use for the SNL model. We will do some test and try to take a movie of it. Hopefully, we will become all expert in intraganglionic injections in few months 😉 ---
**Author:** ![achamess](https://yyz2.discourse-cdn.com/flex030/user_avatar/forum.painresearcher.net/achamess/32/534_2.png) [@achamess](https://forum.painresearcher.net/u/achamess)\ **Post date:** [July 12, 2016, 5:11pm UTC](https://forum.painresearcher.net/t/intraganglionic-injections-into-mouse-drg/56/3 "2016-07-12T17:11:34Z")
Thanks @tberta. Looking forward to what you find. We’re going to try as well using a small dental drill to create an open trajectory to the DRG. I’ll try to take videos/pictures. ---
**Author:** ![marvizon](https://yyz2.discourse-cdn.com/flex030/user_avatar/forum.painresearcher.net/marvizon/32/211_2.png) [@marvizon](https://forum.painresearcher.net/u/marvizon)\ **Post date:** [October 29, 2018, 8:16pm UTC](https://forum.painresearcher.net/t/intraganglionic-injections-into-mouse-drg/56/4 "2018-10-29T20:16:51Z")
Any progress on this? I am trying to do DREADD in DRG neurons using the Nav1.8-cre mouse line. The problem is how to get the AAV vector to the DRG. In my case, intrathecal injection may work because Nav1.8 is specific of sensory neurons. However, we have not been successful in delivering the AAV vector intrathecally to mice. ---
**Author:** ![achamess](https://yyz2.discourse-cdn.com/flex030/user_avatar/forum.painresearcher.net/achamess/32/534_2.png) [@achamess](https://forum.painresearcher.net/u/achamess)\ **Post date:** [October 29, 2018, 8:22pm UTC](https://forum.painresearcher.net/t/intraganglionic-injections-into-mouse-drg/56/5 "2018-10-29T20:22:29Z")
Hi @marvizon Some labs do intra-DRG injections, but it’s a delicate technique that I myself have not mastered. But if you just want to hit DRG, it’s not necessary, unless you really just want a particular DRG (say, left L5 DRG). Intrathecal works very well, but it is dependent on **titer and serotype and promoter**. Many labs have found that **AAV9** in the 10^13 vg/ml range (10 ul typical dose) works very well intrathecally. I’ve done this myself. Which DRGs do you want to hit? Here is the original reference that I used for my own work: > **[Biodistribution of adeno-associated virus serotype 9 (AAV9) vector after...](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4051274/)** > > Adeno-associated virus serotype 9 (AAV9)-mediated gene transfer has been reported in central nervous system (CNS) and peripheral tissues. The current study compared the pattern of expression of Green Fluorescent Protein (GFP) across the mouse CNS and... Recently, this paper found that you can use AAV9 **intraplantar** and get good retrograde transduction. The key is \< P5 animals. I haven’t done this myself although I want. [https://www.cell.com/cell-reports/pdf/S2211-1247(18)30624-7.pdf](https://www.cell.com/cell-reports/pdf/S2211-1247(18)30624-7.pdf) I’d do the intrathecal route. You need high titer AAV9 though. I’ve had the best success with AAV from Penn vector core. Addgene distributes their stocks now and makes their vectors. It looks like Addgene carries Cre-dependent inhibitory (hm4di) DREADD in AAV9 but not the activating ones. So you may need a custom prep. Make sure it’s 10^13 vg/ml. I haven’t had success with less. See the reference above too. The issue here though is the hSyn promoter. It works, but not amazingly in DRG. CAG is better. See this discussion > [@Adeno-associated Virus-mediated Transgene Expression in Genetically Defined Neurons of the Spinal Cord](https://forum.painresearcher.net/t/adeno-associated-virus-mediated-transgene-expression-in-genetically-defined-neurons-of-the-spinal-cord/451): > > Very nice new resource. Useful for people working with virus. > **[Addgene: Chemogenetics AAV Preps](https://www.addgene.org/viral-service/aav-prep/chemogenetics/)** > > Ready-to-use AAV available from Addgene's viral service encoding chemogenetics tools. Good luck. Let us know how it goes. ---
**Author:** ![marvizon](https://yyz2.discourse-cdn.com/flex030/user_avatar/forum.painresearcher.net/marvizon/32/211_2.png) [@marvizon](https://forum.painresearcher.net/u/marvizon)\ **Post date:** [October 29, 2018, 8:28pm UTC](https://forum.painresearcher.net/t/intraganglionic-injections-into-mouse-drg/56/6 "2018-10-29T20:28:51Z")
Thanks a lot! I have almost given up on this. We will try a control vector to see if we can get reporter gene expression in the DRG. Then we will be able to order the custom vector using a gene from addgene. I’ll read through the info you provided and come back to you. Great site, BTW! ---
**Author:** ![achamess](https://yyz2.discourse-cdn.com/flex030/user_avatar/forum.painresearcher.net/achamess/32/534_2.png) [@achamess](https://forum.painresearcher.net/u/achamess)\ **Post date:** [October 29, 2018, 8:34pm UTC](https://forum.painresearcher.net/t/intraganglionic-injections-into-mouse-drg/56/7 "2018-10-29T20:34:06Z")
Hi @marvizon Thanks for the kind words. Please tell your colleagues and students about this site! The more people the better. That is a good plan. I recommend this Cre-dependent tomato vector to test. [https://www.addgene.org/100048/](https://www.addgene.org/100048/) If you’re feeling adventurous and want broad dissemination of your AAV in the PNS (not just DRG), you may try the PHP.S serotype from the Gradinaru lab at Caltech. Addgene also offers this. You need to do an intravenous injection. Intrathecal would probably also work but you won’t get the wide spread as IV, I imagine. [https://www.addgene.org/28306/](https://www.addgene.org/28306/) > > > Adeno-associated viruses (AAVs) are commonly used for in vivo gene transfer. Nevertheless, AAVs that provide efficient transduction across specific organs or cell populations are needed. Here, we describe AAV-PHP.eB and AAV-PHP.S, capsids that efficiently transduce the central and peripheral nervous systems, respectively. In the adult mouse, intravenous administration of 1 × 1011 vector genomes (vg) of AAV-PHP.eB transduced 69% of cortical and 55% of striatal neurons, while 1 × 1012 vg of AAV-PHP.S transduced 82% of dorsal root ganglion neurons, as well as cardiac and enteric neurons. The efficiency of these vectors facilitates robust cotransduction and stochastic, multicolor labeling for individual cell morphology studies. To support such efforts, we provide methods for labeling a tunable fraction of cells without compromising color diversity. Furthermore, when used with cell-type-specific promoters and enhancers, these AAVs enable efficient and targetable genetic modification of cells throughout the nervous system of transgenic and non-transgenic animals. ---
**Author:** ![marvizon](https://yyz2.discourse-cdn.com/flex030/user_avatar/forum.painresearcher.net/marvizon/32/211_2.png) [@marvizon](https://forum.painresearcher.net/u/marvizon)\ **Post date:** [November 1, 2018, 1:09am UTC](https://forum.painresearcher.net/t/intraganglionic-injections-into-mouse-drg/56/8 "2018-11-01T01:09:39Z")
My final objective is to deliver Gs DREADD to the DRG, in order to increase cAMP levels. There are no ready-made AAV vectors for Gs yet, so we will need to get the plasmid from Addgene and have the vector custom-made. However, what I need right now is to get preliminary data for a grant proposal to show that is feasible to infect DRG. So, to answer your question, we want to target all DRG. Nav1.8-Cre will ensure selective expression in nociceptors. We have the Nav1.8-Cre mice. > > > The latent sensitization model of chronic pain reveals that recovery from some types of long-term hyperalgesia is an altered state in which nociceptive sensitization persists but is suppressed by the ongoing activity of analgesic receptors such as μ-opioid receptors (MORs). To determine whether these MORs are the ones present in nociceptive afferents, we bred mice expressing Cre-recombinase under the Nav1.8 channel promoter (Nav1.8cre) with MOR-floxed mice (flMOR). These Nav1.8cre/flMOR mice had reduced MOR expression in primary afferents, as revealed by quantitative PCR, in situ hybridization, and immunofluorescence colocalization with the neuropeptide calcitonin gene-related peptide. We then studied the recovery from chronic pain of these mice and their flMOR littermates. When Nav1.8cre/flMOR mice were injected in the paw with complete Freund adjuvant they developed mechanical hyperalgesia that persisted for more than 2 months, whereas the responses of flMOR mice returned to baseline after 3 weeks. We then used the inverse agonist naltrexone to assess ongoing MOR activity. Naltrexone produced a robust reinstatement of hyperalgesia in control flMOR mice, but produced no effect in the Nav1.8/flMOR males and a weak reinstatement of hyperalgesia in Nav1.8/flMOR females. Naltrexone also reinstated swelling of the hind paw in flMOR mice and female Nav1.8cre/flMOR mice, but not male Nav1.8cre/flMOR mice. The MOR agonist DAMGO inhibited substance P release in flMOR mice but not Nav1.8cre/flMOR mice, demonstrating a loss of MOR function at the central terminals of primary afferents. We conclude that MORs in nociceptive afferents mediate an ongoing suppression of hyperalgesia to produce remission from chronic pain. The paper by the Vulchanova group is very encouraging but, as you said, the issue is whether the hSyn promoter will work as well as the CB7 promoter that they used. What did you get using hSyn in DRG? We could buy this vector from Addgene [AAV-hSyn-DIO-hM3Dq-mCherry](https://www.addgene.org/44361/) with a AAV9 capside at 10^13 vg. Will it work? Or we could get the same vector used by the Vulchanova lad from Addgene [https://www.addgene.org/105542/](https://www.addgene.org/105542/) But this will not tell us if the DREADD vectors with hSyn promoters will work. Any thoughts? ---
**Author:** ![achamess](https://yyz2.discourse-cdn.com/flex030/user_avatar/forum.painresearcher.net/achamess/32/534_2.png) [@achamess](https://forum.painresearcher.net/u/achamess)\ **Post date:** [November 1, 2018, 2:17pm UTC](https://forum.painresearcher.net/t/intraganglionic-injections-into-mouse-drg/56/9 "2018-11-01T14:17:03Z")
@marvizon > My final objective is to deliver Gs DREADD to the DRG, in order to increase cAMP levels. There are no ready-made AAV vectors for Gs yet, so we will need to get the plasmid from Addgene and have the vector custom-made. However, what I need right now is to get preliminary data for a grant proposal to show that is feasible to infect DRG OK. Yes, you’ll need to have that custom made. Regarding your prelim data needs: Infecting DRGs w/ AAV intrathecally is well-accepted now. I don’t think anyone would doubt you could do it (although the prickly-ness of reviewers can never be fully predicted). If it were a more niche technique, I’d say show it. But if you just want to show you can infect DRGs, get that control vector (GFP or tomato) from Addgene and do it. It will take 2-3 weeks (preferably 3 weeks) to see expression. Keep that in mind > So, to answer your question, we want to target all DRG. Nav1.8-Cre will ensure selective expression in nociceptors. We have the Nav1.8-Cre mice. So you want DRGs throughout the whole body? Maybe then you should try that new PHP.S vector. But that will hit non-DRGs as well. Alternatively, many labs have injected high titer AAV intraperitoneal at P1 and get wide DRG expression. See this nice paper from Fan Wang’s lab > **[A craniofacial-specific monosynaptic circuit enables heightened affective pain...](https://pubmed.ncbi.nlm.nih.gov/29184209/)** > > Humans often rank craniofacial pain as more severe than body pain. Evidence suggests that a stimulus of the same intensity induces stronger pain in the face than in the body. However, the underlying neural circuitry for the differential processing of... > The paper by the Vulchanova group is very encouraging but, as you said, the issue is whether the hSyn promoter will work as well as the CB7 promoter that they used. What did you get using hSyn in DRG? See this post. That’s what I get with hSyn GFP. This is a high titer AAV from Penn (10^13). You can see there is nice expression, but many DRGs don’t have infection. I think CB7/CAG/CBh would have much higher expression. > [@Stuff I tried during grad school/post-doc that won't get published but could be useful](https://forum.painresearcher.net/t/stuff-i-tried-during-grad-school-post-doc-that-wont-get-published-but-could-be-useful/302/10): > > Intrathecal AAV9 works excellently to get DRG neurons in the lumbar region. I injected the same AAV-hSyn-EGFP (10^13), 10 ul, and got very high expression. In light of the recent work looking at promoters in DRGs, I bet CAG would have been even better. However, it also hits spinal neurons and probably higher CNS areas (as reported) [drg\_dapi\_10x\_1] [lsc-20x-edf\_1c1 copy] Spinal cord > We could buy this vector from Addgene [AAV-hSyn-DIO-hM3Dq-mCherry](https://www.addgene.org/44361/) with a AAV9 capside at 10^13 vg. Will it work? Or we could get the same vector used by the Vulchanova lad from Addgene [https://www.addgene.org/105542/](https://www.addgene.org/105542/) But this will not tell us if the DREADD vectors with hSyn promoters will work. The titer is good. That’s what you want. It will infect, just the hSyn promoter will dampen the expression. See this paper, and also my image in the thread above. So it depends on how much expression you need. > [@Adeno-associated Virus-mediated Transgene Expression in Genetically Defined Neurons of the Spinal Cord](https://forum.painresearcher.net/t/adeno-associated-virus-mediated-transgene-expression-in-genetically-defined-neurons-of-the-spinal-cord/451): > > Very nice new resource. Useful for people working with virus. If you want high expression of the DREADD transgene, you may need to: - Order the plasmid - Make a new plasmid by cloning the DREADD transgene into an AAV backbone with a different promoter, or oppositely, clone in a CAG/CB7/CBh promoter into the hSyn - Get a custom prep made of the virus. You may also look in the literature to see if anyone already made such a plasmid. I imagine they did. You could request it, and then have your vector made. Good luck. ---
**Author:** ![achamess](https://yyz2.discourse-cdn.com/flex030/user_avatar/forum.painresearcher.net/achamess/32/534_2.png) [@achamess](https://forum.painresearcher.net/u/achamess)\ **Post date:** [November 1, 2018, 2:19pm UTC](https://forum.painresearcher.net/t/intraganglionic-injections-into-mouse-drg/56/10 "2018-11-01T14:19:58Z")
You may also try to request this mouse > > > Hundreds of hormones and ligands stimulate cyclic AMP (cAMP) signaling in different tissues through the activation of G-protein-coupled receptors (GPCRs). Although the functions and individual effectors of cAMP signaling are well characterized in many tissues, pleiotropic effects of GPCR agonists limit investigations of physiological functions of cAMP signaling in individual cell types at different developmental stages in vivo To facilitate studies of cAMP signaling in specific cell populations in vivo, we harnessed the power of DREADD (designer receptors exclusively activated by designer drugs) technology by creating ROSA26-based knock-in mice for the conditional expression of a Gs-coupled DREADD (rM3Ds-green fluorescent protein \[GFP\], or "GsD"). After Cre recombinase expression, GsD is activated temporally by the administration of the ligand clozapine N-oxide (CNO). In the same allele, we engineered a CREB-luciferase reporter transgene for noninvasive bioluminescence monitoring of CREB activity. After viral delivery of Cre recombinase to hepatocytes in vivo, GsD is expressed and allows CNO-dependent cAMP signaling and glycogen breakdown. The long-term expression of GsD in the liver results in constitutive CREB activity and hyperglycemia. ROSA26-Gs-DREADD mice can be used to study the physiological effects of cAMP signaling, acute or chronic, in liver or any tissue or cell type for which transgenic or viral Cre drivers are available. ---
**Author:** ![DaraBree](https://avatars.discourse-cdn.com/v4/letter/d/aca169/32.png) [@DaraBree](https://forum.painresearcher.net/u/DaraBree)\ **Post date:** [January 9, 2020, 2:13pm UTC](https://forum.painresearcher.net/t/intraganglionic-injections-into-mouse-drg/56/11 "2020-01-09T14:13:21Z")
@marvizon @achamess Just jumping in here for a second and sort of in relation to my previous post. Have you ever heard or seen or done an intrathecal injection of an AAV construct with any neuron specific promoter which then goes to the DRG and then travels along peripheral nerves to the periphery via anterograde transport? In theory this should/could happen but obviously in practice things can turn out much differently. I have an idea to try it but was wondering if you had any thoughts? ---
**Author:** ![achamess](https://yyz2.discourse-cdn.com/flex030/user_avatar/forum.painresearcher.net/achamess/32/534_2.png) [@achamess](https://forum.painresearcher.net/u/achamess)\ **Post date:** [January 9, 2020, 2:19pm UTC](https://forum.painresearcher.net/t/intraganglionic-injections-into-mouse-drg/56/12 "2020-01-09T14:19:27Z")
Sure. IT injection of AAV9 is very effective. Where the transgene goes depends on what the transgene is. But any standard fluorescent protein will go out to the periphery. May take longer but it occurs. ChR2 is membrane localized and looks especially nice. the virus itself probably doesnt make it all the way out to the periphery at high numbers but that’s not what you’re looking for. You want your transgene to get out there after it’s been produced at the soma. So yes, what you’re asking is the default behavior, in my experience. But some genes will be better than others. Also promoters matter. hSyn works in DRG but not amazingly. Might be better to use a Cre mouse and inject a Cre-dependent virus using CAG promoter ---
**Author:** ![DaraBree](https://avatars.discourse-cdn.com/v4/letter/d/aca169/32.png) [@DaraBree](https://forum.painresearcher.net/u/DaraBree)\ **Post date:** [January 9, 2020, 2:29pm UTC](https://forum.painresearcher.net/t/intraganglionic-injections-into-mouse-drg/56/13 "2020-01-09T14:29:15Z")
Ok great thanks. Cre mouse with Cre-dependent CAG promoter might be the best way to go but we don’t have those mice so likely will try hSyn or PGP9.5 with AAV9 first. Thanks again ---
**Author:** ![marvizon](https://yyz2.discourse-cdn.com/flex030/user_avatar/forum.painresearcher.net/marvizon/32/211_2.png) [@marvizon](https://forum.painresearcher.net/u/marvizon)\ **Post date:** [January 9, 2020, 7:02pm UTC](https://forum.painresearcher.net/t/intraganglionic-injections-into-mouse-drg/56/14 "2020-01-09T19:02:23Z")
![image](https://canada1.discourse-cdn.com/flex030/uploads/painresearcher/original/1X/95bab583125c125903a51aa38c82e6746d60fe35.png) ---
**Author:** ![marvizon](https://yyz2.discourse-cdn.com/flex030/user_avatar/forum.painresearcher.net/marvizon/32/211_2.png) [@marvizon](https://forum.painresearcher.net/u/marvizon)\ **Post date:** [January 9, 2020, 7:12pm UTC](https://forum.painresearcher.net/t/intraganglionic-injections-into-mouse-drg/56/15 "2020-01-09T19:12:33Z")
The top 2 panels (A and B) replicate in my lab the findings of this paper: Schuster, D J, J A Dykstra, M S Riedl, K F Kitto, L R Belur, R S McIvor, R P Elde, C A Fairbanks, L Vulchanova. Biodistribution of adeno-associated virus serotype 9 (AAV9) vector after intrathecal and intravenous delivery in mouse. Frontiers in neuroanatomy 8: 42-42 (2014). PMC4051274 Note that the construct uses the CB7 promoter and AAV9. We didn’t examine the periphery but got nice staining with eGFP of the axons going into the dorsal horn (panel B) For panels C and D we used mice expressing Cre in CRF-expressing neurons. CRF expression is poor in DRG, but we had these mice so we tried them. We saw expression of mCherry in a few DRG neurons, consistent with the reported expression of CRF. Many spinal cord neurons also expressed mCherry, presumably because these are the neurons that express CRF. ---
**Author:** ![DaraBree](https://avatars.discourse-cdn.com/v4/letter/d/aca169/32.png) [@DaraBree](https://forum.painresearcher.net/u/DaraBree)\ **Post date:** [January 9, 2020, 7:28pm UTC](https://forum.painresearcher.net/t/intraganglionic-injections-into-mouse-drg/56/16 "2020-01-09T19:28:01Z")
Thanks. I saw this paper and was asking myself did they check in the periphery. I’ve used mCherry to good effect before so will likely go with that again ---
**Author:** ![marvizon](https://yyz2.discourse-cdn.com/flex030/user_avatar/forum.painresearcher.net/marvizon/32/211_2.png) [@marvizon](https://forum.painresearcher.net/u/marvizon)\ **Post date:** [January 9, 2020, 7:34pm UTC](https://forum.painresearcher.net/t/intraganglionic-injections-into-mouse-drg/56/17 "2020-01-09T19:34:19Z")
If you have a bit of money you could buy peripherin-Cre or advillin-Cre mice from JAX and then inject them with an AAV9 hSyn DIO vector from Addgene. Depends on what you want to do. ---
**Author:** ![nikhayes](https://avatars.discourse-cdn.com/v4/letter/n/ec9cab/32.png) [@nikhayes](https://forum.painresearcher.net/u/nikhayes)\ **Post date:** [November 13, 2023, 4:55pm UTC](https://forum.painresearcher.net/t/intraganglionic-injections-into-mouse-drg/56/18 "2023-11-13T16:55:13Z")
There was a recent paper that injected PHP.s intrathecally and the results looked good. [https://www.cell.com/cell/pdf/S0092-8674(23)00739-0.pdf](https://www.cell.com/cell/pdf/S0092-8674(23)00739-0.pdf) Also this paper with serotypes with improved results with DRG/Nodose [https://www.sciencedirect.com/science/article/pii/S0896627322004111](https://www.sciencedirect.com/science/article/pii/S0896627322004111) Now I’m just interested in finding the best promoter to test that isnt as large as CAG… maybe will try CB7, CBh or CBA P.S. sorry I’m posting pretty much the same information here and in another thread about promoters ---
**Author:** ![achamess](https://yyz2.discourse-cdn.com/flex030/user_avatar/forum.painresearcher.net/achamess/32/534_2.png) [@achamess](https://forum.painresearcher.net/u/achamess)\ **Post date:** [November 19, 2023, 12:31pm UTC](https://forum.painresearcher.net/t/intraganglionic-injections-into-mouse-drg/56/19 "2023-11-19T12:31:44Z")
Thanks for the info @nikhayes. I know there is interest in these new serotypes of the PHP variety. We have had previous discussion here about variability. Maybe the new ones are better. > [@Systemic Administration of AAV PHP.S for Delivery to DRG](https://forum.painresearcher.net/t/systemic-administration-of-aav-php-s-for-delivery-to-drg/898): > > Has anyone used AAV-PHP.S in neonatal mice (P1) via the intraperitoneal route for delivery to DRG? In the original paper, they do IV admin and the transduction is great, but IP may be easier and it saves us some time while the animals come of age. @liz @tberta @thicunha ---
**Author:** ![PatriciaT](https://yyz2.discourse-cdn.com/flex030/user_avatar/forum.painresearcher.net/patriciat/32/522_2.png) [@PatriciaT](https://forum.painresearcher.net/u/PatriciaT)\ **Post date:** [May 8, 2024, 2:47pm UTC](https://forum.painresearcher.net/t/intraganglionic-injections-into-mouse-drg/56/20 "2024-05-08T14:47:30Z")
I’m currently starting an experimental line in which I need to infect DRGs of some Cre mice, and I cannot express how thankful I am for this entire thread 💜 [Next page](https://forum.painresearcher.net/t/intraganglionic-injections-into-mouse-drg/56.md?page=2)